Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$$Money_Train_Leaving_Station
¤*¨¨*¤.¸¸…¸.¤\
\¸ ? AMBS ?.,.\
.\¸.¤*¨¨*¤.¸¸.¸.¤*
..\
?/
/¦
/ \
Amarantus' LymPro Could Be A Game-Changer For Alzheimer's Diagnosis
http://seekingalpha.com/article/1347691-amarantus-lympro-could-be-a-game-changer-for-alzheimers-diagnosis
GET ON THE MONEY TRAIN -Choo Choo
AMBS is moving .073 cents plus tax, get yourself a boat load
UP-List Time Line
Well lets see, uplist from .07 cents, huh how we gonna do that.
Well the CEO or Company needs to announce a Joint venture to market LymPro. One Year? not sure
The Company or CEO needs to announce a Orphan Status with Eltoprozine - Time 1 year?
So these two molecular items need further advancement to get a .07 stock to .70 cents, then for example a Reverse 10 for one stock split, your 100,000 shares are 10,000 shares at $7.00 dollars.
If you had 100,000 shares valued at .70 $70,000 at the time of the reverse split your new 10,000 shares would be $7.00 a share.
So now your uplisted with $70k grand of stock.
the only problem is getting the .07 cent stock to .70 cents.
SHOW ME THE MONEY
Where is the money going? Flights to New York
Why are we filing late on a regular basis? Disorganized
What are the employees doing to earn salaries? Company sells shares
What are you doing to earn your quarter mil salary? read reports
(Where is the hole in the boat?) CEO
When are revenues expected? End of Year
How long before AMBS needs more money? Every 3-6 months (planned burn rate)
What milestones need to be reached to uplist?
a. Approval and Lympro marketing
b. Eltorprazine Orphan Status
c. MANF more indications
Hiring a Series of Stock Promoters to get the real story out in mass might be an idea, but the other function of the financiing company would be to promote, sell the concepts and shares to their investors but why, when you can buy at .03 and sell at .12.
SO MONEY RUNNERS? NOPE, how about GoldmanSachs.
"roadmap for ultimate regulatory approval for LymPro"
On March 20th, 2014, the FDA approved an amyloid imaging agent being developed by Piramal Imaging’s Neuraceq®, the third such approval at the FDA on the heels of approvals for Avid Radiopharmaceuticals and GE. We believe this approval represents a shift in the agency’s thinking regarding biomarkers for Alzheimer’s disease, and is a statement regarding the importance of new products in the quickly evolving ‘gold standard’ in-life diagnostic paradigm for Alzheimer’s disease. As a result, we will be working closely with Dr. Kirby and our other advisors to prepare updated clinical development protocols and provide the most compelling data to our early customers for LymPro: pharmaceutical companies and Key Opinion Leading physicians. We are currently seeking counsel with our regulatory consultants regarding the appropriate FDA strategy, and expect to initiate a dialogue with the agency upon completion of the APP for LymPro. We are hopeful this dialogue will ultimately facilitate FDA approval for LymPro and catalyze market penetration. In total, 900 total patient samples were required for FDA approval of Neuraceq between disease and control arms, and we believe this may serve as a roadmap for ultimate regulatory approval for LymPro. - See more at: http://www.thechairmansblog.com/company_post/commercialization-track-2014-updating-lympro-test-progress/?utm_source=rss&utm_medium=rss&utm_campaign=commercialization-track-2014-updating-lympro-test-progress#sthash.Qisnk9Fa.dpuf
DEVELOPMENT PLAN
The Company intends to commercialize LymPro as a Laboratory Developed Test (“LDT”) under the Clinical Laboratory Improvement Amendments (“CLIA”) in the second half of 2014 in the United States. As part of the commercialization process, the Company is actively evaluating its options with respect to appropriate CLIA labs, as it does not intend to build its own laboratory for this purpose. Thereafter, the Company will evaluate its options with respect to ex-US commercialization of LymPro as well as ultimate FDA approval and marketing of LymPro in the United States. The Company is currently establishing its commercial supply-chain for LymPro’s commercialization.
The Company intends initiate Phase 2 or Phase 3 clinical studies for Eltoprazine in the areas of PD LID and/or Adult ADHD in 2014 based on assessments the Company is currently conducting. The Company is currently sourcing contract manufacturers for clinical-grade material of Eltoprazine and is establishing study designs for the initiation of our next clinical studies. In addition, the Company has sourced the necessary vendors to allow the Company to be in compliance with worldwide regulatory standards.
The Company intends to continue the development of MANF, with a specific view towards orphan indications. The Company will continue the development of MANF in the areas of retinitis pigmentosa, Parkinson’s disease, and Wolfram Syndrome..
http://ih.advfn.com/p.php?pid=nmona&article=61911260
"commercialize LymPro"
"I am extremely pleased to be joining Amarantus at this key point in LymPro's development as we prepare to commercialize LymPro in the 2nd half of 2014," said Dr. Kirby, Amarantus' newly appointed corporate advisor. "The need for objective, non-invasive, and reliable Alzheimer's biomarkers is at an all-time high. The FDA's recent decision to approve a 3rd amyloid imaging agent for adjunctive aid to the diagnosis of Alzheimer's disease demonstrates an acute understanding of the value of incremental improvements in the disease's diagnostic paradigm. We believe the LymPro Test® has the potential to be significantly more valuable in terms of specific information provided to the physician, while simultaneously being drastically less expensive. This combination could provide tremendous value to the healthcare system as we look for new ways to care for patients, as well as facilitate the development of therapeutic products that could ultimately alter the course of the disease."
http://ir.stockpr.com/amarantus/company-news/detail/1194/amarantus-appoints-dr-louis-kirby-to-board-of-advisors
" We have found that MANF can protect and stimulate proliferation of b -cells in a mouse model of type 1 diabetes. In addition, we generated mice which lack MANF protein, resulting in development of T1D. Since MANF has direct effects of mouse b -cells and is expressed and regulated in human b - cells we hope that MANF has therapeutic potential for the treatment of T1D, where b -cell protecting and regenerating therapies are not available" says Professor Mart Saarma.
Text: Maria Lindahl
The Juvenile Diabetes Research Foundation (JDRF) has awarded a research grant of $ 495 000 for three years for supporting a collaborative team headed by Professor Mart Saarma at the Institute of Biotechnology, University of Helsinki and Professor Timo Otonkoski at Biomedicum Stem Cell Center. The aim of the project is to study therapeutic potential of neurotrophic factor MANF (Mesencephalic Astrocyte-derived Neurotrophic Factor) in preclinical research for type 1 diabetes. The therapeutic effect of MANF will be studied using rodent and human pancreatic islets, b -cell lines and in rodent models of diabetes.
Professor Mart Saarma's team is currently studying the structure, biology and therapeutic potential of neurotrophic factors GDNF, CDNF and MANF for neurodegenerative diseases. The indication for neurotrophic factor MANF to be a candidate therapeutic factor for diabetes came from Dr. Maria Lindahl´s work (Saarma group, Institute of Biotechnology). These studies showed that Manf-deficient mice were diabetic due to progressive loss of insulin-producing pancreatic b -cells. The team in the collaborative project includes top experts in the fields of endocrinology, neurosciences and genetic engineering of mice.
Prof. Timo Otonkoski is a pediatrics endocrinologist whose research topic for many years has been in the development and renewal of insulin-producing pancreatic b -cells. Dr. Maria Lindahl´s research has focused on the role of neurotrophic factors in the endocrine system by developing and analysing several genetically modified mice models. Dr. Jari Rossi (Institute of Biomedicine) has extensive experience in genetically engineered mice, and studying energy balance and metabolism. Doctoral students M.Sc. Tatiana Danilova and MD Erik Palm will be tightly involved in the project by working on cell lines, rodent islets and mouse models. MD Elina Hakonen will focus on human islets and cell lines.
JDRF is the leading global organization funding type 1 diabetes (T1D) research. JDRF's goal is to progressively remove the impact of T1D from people's lives until we achieve a world without T1D.
One of the main goals in type 1 diabetes therapy is to define a method for functional b -cell proliferation and regeneration.
http://www.biocenter.helsinki.fi/bi/research/
Emer Leahy, Ph.D., President & CEO of PsychoGenics said “The results of this trial are compelling and show that eltoprazine has the potential to address a critical unmet need in Parkinson’s disease. We are happy to have collaborated with Dr. Andres Bjorklund, a renowned expert in the LID field and a member of the Scientific Advisory Board of The Michael J. Fox Foundation. We are also very appreciative of the support from the Michael J. Fox Foundation. With these promising positive data we now intend to progress eltoprazine to market as quickly as possible with support from a partner”.
“Dyskinesia is a top priority for the Foundation because of its impact on the quality of life of people living with Parkinson’s disease,” said Todd Sherer, PhD, CEO of The Michael J. Fox Foundation. “The results presented by PsychoGenics and Dr. Bjorklund show early promise in finding a potential treatment for dyskinesia, and we look forward to working with this team to drive their program forward.”
Anders Bjorklund, MD, Ph.D., Wallenberg Neuroscience Center, University of Lund, Sweden said “There is extensive evidence for the role of serotonin neurons in the induction and maintenance of LID. We have shown that 5-HT1A and 5-HT1B agonists have a synergistic effect in suppressing LID in preclinical models. Doses of 5-HT1A and 5-HT1B receptor agonists, which individually produced a reduction in dyskinesia, were able to further significantly reduce dyskinesia severity when administered in combination, without affecting the anti-parkinsonian properties of levodopa. The results of this clinical are encouraging and in line with the data generated in animal models.”
http://www.businesswire.com/news/home/20120612005589/en/PsychoGenics-Announces-Positive-Efficacy-Data-Levodopa-Induced#.U1VeO_ldXQM
Racc1, its market makers business, not to worrry.
About Eltoprazine and its role in dyskinesias
Serotonin neurons are known to be able to convert levodopa to dopamine, as well as store and release dopamine in an activity-dependent manner. In advanced patients, where the dopamine terminals have largely degenerated, serotonin terminals are considered a major source of dopamine release. However, serotonin neurons lack feedback control mechanisms for the release of dopamine, such as the D2 autoreceptor and the dopamine transporter, which normally regulate the synaptic level of dopamine within a physiological range. Administration of levodopa, therefore generates high swings in synaptic dopamine, causing pulsatile stimulation of post-synaptic dopamine receptors, and the appearance of dyskinesia. Preclinical research has shown that removal of the serotonin innervation or activation of pre-synaptic receptors of the serotonin neurons by a combination of 5-HT1A and 5-HT1B receptor agonists produces a suppression of LID. On the basis of these findings it was logical to test eltoprazine in a LID clinical trial.
http://www.businesswire.com/news/home/20120612005589/en/PsychoGenics-Announces-Positive-Efficacy-Data-Levodopa-Induced#.U1VeO_ldXQM
"700 patients to date" - Eltoprazine is a 5HT1a/1b partial agonist small molecule drug candidate has a well-established safety profile, having been dosed in over 700 patients to date. The study entitled "The Effects of Eltoprazine on Symptoms of Attention Deficit Hyperactivity Disorder (ADHD) in Adults: A Double-Blind, Multiple Dose, Crossover, Safety and Preliminary Efficacy Trial" enrolled 47 patients (48 enrollees were planned), with 36 patients completing the study. The study was conducted at 4 centers in the United States, including Duke University Medical Center, Riley Hospital for Children, NeuroScience, Inc. and UCI Child Development Center.
Read more: Amarantus Announces Positive Phase 2a Data for Eltoprazine in Adult ADHD - FierceBiotech http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd#ixzz2zXoaMes5
Subscribe at FierceBiotech
http://www.fiercebiotech.com/press-releases/amarantus-announces-positive-phase-2a-data-eltoprazine-adult-adhd
In-Licensed Levadopa-Induced Dyskinesia Phase 2b-Ready Eltoprazine from PGI Drug Discovery
What is the market size for Levadopa-Induced Dyskinesia
Please Add to Shareholders Questions
Announced Positive Phase 2a Data for Eltoprozine in LID
What is the market size for Eltoprozine?
Established LymPro research collaboration with Boston University School of Medicine
What time lines have Boston University given on LymPro Research completion.
Announced positive Phase 2a Data for Eltoprazine in adult ADHD
Market Size for Eltoprazine in adult ADHD
Acquired exclusive option to license intellectual property for use of MANF and CDNF to treat Antibiotic-Induced Ototoxicity
Market size for MANF and CDNF to treat Antibiotic-Induced Ototoxicity
What other types of diagnosis treatments can be expeceted to be released for MANF in 2014 and how long to develop?
Start a Shareholders Question list for Thursday.
Thanks WarpCore, that why your the warp.
I'm buying all that I can fit into my pocket.
MONEY TRAIN LEAVING STATION
I'm long AMBS only sold once from .02 to .18 a couple years ago.
It's Easter Weekend, recent Blood Moon new CFO
I understand, AMBS HAS NOT CHANGED
IM BUYING MORE
GERALD the Dogs are Barking
Pack up your things, going back to Football.
Keep walking and buy some more AMBS
We need the Novo Nordisk, Amgen, Gilead Sciences,
JNJ, Even Teva Pharmaceutical Industries of Israel.
To join hands and pump out the products.
I think before the year is out, GC will be gone,
and we have a new CEO - ZoomBoom.
OH, my GOSH we have a over-sold situation
Hope the 10-k Annual Report comes out today.
Who is the Auditor by the way for AMBS.
I"m buying into next week as well some more
here and there. Even though I"m very upset with Management
for this failure, I"m buying their shares as I still believe
in the over-riding believe that several Molecules they
have are going to pan out. And certainly the LymPro
Diagnostic Tools.
Hope GC has E&O Insurance he's going to need it.
"Error's & Ommissions" used by executives to protect themselves when they screw up like this.
Share-Holders Meeting? When where again?
Lets double down the bet or increase your holdings. Hold Gerald Accountable, when is the share-holders meeting again?
Share-Holders Meeting? When where again?
Lets double down the bet or increase your holdings. Hold Gerald Accountable, when is the share-holders meeting again?
Easter on the door step. I'll let this one pass,
and give AMBS ONE MORE FRICKING CHANCE to GET
Documents, Taxes, employee's in order. Get the news out!!
I just think its so Bernie Maddoff like to tweet information about your Annual Report to select investors.
Has anyone called the Company Office? Is it Open?
Are they still in business?
What about Lincoln Investors what do they think.
I would assume they are discussing removing GC now.
This board has about what 50million shares, 10% we have some say.
Get rid of this GREEN HORN CEO Fire him. Get a new one.
I bought 100,000 more this week
Yes in ZOOMBoom We Trust. GC Get a new job.
I'll pay for pizza till 10k is done
Lets say we make it to NASDAQ, and GC does not file on time
you know what they do to Bio-Tech with late filings?
This guy is a trashy leader. I'm voting him OFF.
Anybody can make a phone call and arrange a license agreement.
His Daddy is doing all the work anyway.
Building Shareholder value - show me.
How about GC step down. Late filing? Really?
Does GC actually run this or is it his Daddy.
ITS TIME TO UPLIST from .07 to $2.00. Bring on News.
This is totally Unacceptable. GC Needs a dose of MANF.
Filing Lat 10-k after gouging out another 4 million out of a
8 cent penny stock for a bunch of borrowed paper research is
LUDICROUS!
I want some Blood Money for this. AMBS to Moon
I'll return my lunch, buy some 100,000
Nay, warpcore, I"ll let the penny CEO's have their domain.